

AD-A261 707



AD _____

②


ARMY PROJECT ORDER NO: 89PP9961

TITLE: ANALYSIS OF DENGUE VIRUS ENHANCING EPITOPES USING
PEPTIDE ANTIGENS DERIVED FROM THE ENVELOPE GLYCOPROTEIN
GENE SEQUENCE

PRINCIPAL INVESTIGATOR: May C. Chu, Ph.D.

CONTRACTING ORG: Division of Vector-Borne Infectious Diseases
Center for Infectious Diseases
Centers for Disease Control
Atlanta, Georgia 30333

REPORT DATE: November 29, 1991



TYPE OF REPORT: Final Report

PREPARED FOR: U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The findings in this report are not to be construed as an
official Department of the Army position unless so designated by
other authorized documents.

98 3 8 079

93-04960



5400

REPORT DOCUMENTATION PAGE

Form Approved
OMB No 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE 29 Nov 91	3. REPORT TYPE AND DATES COVERED Final Report (9/1/89 - 11/30/91)	
4. TITLE AND SUBTITLE Analysis of Dengue Virus Enhancing Epitopes Using Peptide Antigens Derived From the Envelope Glycoprotein Gene Sequence			5. FUNDING NUMBERS Army Project Order 89PP9961	
6. AUTHOR(S) May C. Chu, Ph.D.			61102A 3M161102BS12.AB.192 WUDA320711	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Division of Vector-Borne Infectious Diseases Center for Infectious Diseases Centers for Disease Control Atlanta, Georgia 30333			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research & Development Command Fort Detrick Frederick, Maryland 21702-5012			10. SPONSORING MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a DISTRIBUTION AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b DISTRIBUTION CODE	
13 ABSTRACT (Maximum 200 words) The biological events leading to the development of severe disease manifestations of dengue infections (dengue hemorrhagic fever/dengue shock syndrome, DHF/DSS) has been the focus of many investigations. Though DHF/DSS cases occur during primary dengue infections, the majority of severe dengue disease has been associated with persons experiencing a secondary heterotypic dengue infection. What do we know about the pathogenic processes that result in the exacerbation of dengue symptoms? Can these factors be identified in vitro and then correlated with clinical disease? The results of previous studies suggest that pre-existing DEN antibodies circulating in a person may be a risk factor in the development of DHF/DSS. However, other host and viral factors must be involved since only a small proportion of the population residing in endemic dengue disease regions develop severe dengue disease.				
14 SUBJECT TERMS Dengue Fever; Nucleotide Sequencing; Peptides; Enhancing Epitopes; RA I; PO; Antigens; Dengue Virus; Analysis			15 NUMBER OF PAGES	
			16 PRICE CODE	
17 SECURITY CLASSIFICATION OF REPORT Unclassified	18 SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19 SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20 LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

Accession For	
NTIS GRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By _____	
Distribution/	
Availability Codes	
Dist	Availability Codes Special
A-1	

TABLE OF CONTENTS

REPORT DOCUMENTATION PAGE i

FOREWORD ii

TABLE OF CONTENTS iii

INTRODUCTION 1
 Summary of previous accomplishments for FY 1990 1

ACCOMPLISHMENTS FOR FY 1990 2
 Examination of FcR-expression in HL-CZ promonocytic and
 enhanced virus replication 2
 Reactivities of anti-DEN-2 E glycoprotein synthetic
 peptide antibodies with DEN-1 and DEN-2 virus 2
 Cloning and sequencing the nucleotides encoding the
 non-structural DEN-1 CV1636/77 genes 3
 Antibody preparation for use in a standardized ADE 3

DISCUSSION 4
 Relevance of epitope mapping using anti-peptide
 antibodies 4
 Analyses of the genetic relatedness of DEN viruses 4
 Future studies. 5

REFERENCES 6

APPENDIX 1 TABLES

APPENDIX 2 FIGURES

APPENDIX 3 ABSTRACTS

APPENDIX 4 PUBLICATIONS
 PERSONNEL

INTRODUCTION

The biological events leading to the development of severe disease manifestations of dengue infections (dengue hemorrhagic fever/dengue shock syndrome, DHF/DSS) has been the focus of many investigations (1,8). Though DHF/DSS cases occur during primary dengue infections, the majority of severe dengue disease has been associated with persons experiencing a secondary heterotypic dengue infection (6,7). What do we know about the pathogenic processes that result in the exacerbation of dengue symptoms? Can these factors be identified *in vitro* and then correlated with clinical disease? The results of previous studies suggest that pre-existing DEN antibodies circulating in a person may be a risk factor in the development of DHF/DSS (9). However, other host and viral factors must be involved since only a small proportion of the population residing in endemic dengue disease regions develop severe dengue disease.

Antibody-dependent enhancement (ADE) of dengue virus (DEN) replication *in vitro* has been proposed as a pathogenic mechanism in the development of DHF/DSS. We believe that enhanced virus replication is an important part of DEN pathogenesis and that ADE is the result of the interplay of host cells, antibody and virus strain. We investigated DEN virus replication in order to define the parameters that could lead to enhanced growth in the presence of antibodies to flaviviruses.

SUMMARY OF PREVIOUS ACCOMPLISHMENTS FOR FY 1990

- ◻ Developed a sensitive ADE assay to examine the interplay of antibody, virus and host cells in DEN replication. Human promonocytic HL-CZ cells supported enhanced DEN replication better than K562 or U937 human cells at low MOIs (10^{-4} - 10^{-6}).
- ◻ Determined that the sensitivity of the HL-CZ cells was related to the number of Fc-receptors (FcRs) and the FcR types (FcR II > FcR III > FcR I) expressed on the cell surface since blocking the FcRs by specific FcR monoclonal antibodies (MAbs) abrogated virus replication.
- ◻ Characterized the abilities of MAbs 4G2 and 3H5 to mediate virus neutralization and enhanced replication. Determined that the MAbs recognizing DEN envelope (E) glycoprotein epitopes were involved in NT and ADE and confirmed the observation that these activities were concentration related rather than epitope-directed.
- ◻ Compared the growth profiles of selected DEN viruses representing epidemiologically important genotypes using our ADE system. Viruses from endemic dengue region (Thailand) were more antibody-dependent than that of viruses from the dengue epidemic region (Caribbean).

- ◻ Attempted to define the antigenic epitopes that mediate ADE and NT by using antibodies raised against DEN-2 E glycoprotein synthetic peptides. We were able to determine that some antipeptide antibody pools were reactive in ADE and/or NT tests, though reactions appeared much weaker than the MAb controls.
- ◻ Continued to determine the nucleotide sequence encoding the non-structural (NS) regions of DEN-1 CV1636/77 virus. Of the regions examined thus far, it appeared that DEN-4 Dominica and DEN-1 CV1636/77 were very similar in the NS region, suggesting that the viruses have evolved closely or that there may be genomic recombination.

ACCOMPLISHMENTS FOR FY 1991

Examination of FcR-expression in HL-CZ promonocytic and enhanced virus replication. Dr. Wu Tse Liu of the National Yang Ming Medical School, Taipei, Taiwan provided us with several lines of HL-CZ cells (14). We compared the virus yields of the uncloned, clone 3 and clone CCC-5 cells. The results of the enhanced growth profile of DEN-2 16681 virus were variable thus suggesting that the permissiveness of the cells to support enhanced virus replication could be intrinsically different. We investigated the discrepancy of virus yield of these cultures and determined that if the ADE results were grouped by >20% FcR-expression (rosetting) and compared with virus yield (>10³ pfu/ml), the presence of rosetting cells was a factor in cell permissiveness (Table 1) as we had demonstrated before when comparing virus growth in U937, K562 or HuPBL cells. However, in a few cases, neither high nor low number of rosettes correlated with virus yield, thus implying that some other factors also affect virus replication. Therefore, in our analyses of ADE results, we only accepted the tests in which 1) virus control cultures (no antibody) contained no visible growth and 2) positive ADE controls of cultures containing antibody produced 10³ pfu/ml virus yield.

Reactivities of anti-DEN-2 E glycoprotein synthetic peptide antibodies with DEN-1 and DEN-2 virus. We have previously determined the reactivities of mouse antibodies immunized with DEN-2 E glycoprotein peptides in PRNT and ADE assays. Though we were able to demonstrate some activity in sera obtained from mice immunized by i.m. and s.c. routes, there was variation between antibody specimens directed against the same peptide from heterologous mouse strains (19). To normalize antibody reactivity, sarcoma-primed BALB/C mice were immunized with individual DEN-2 E glycoprotein synthetic peptides and the resulting mouse ascites fluids (MAFs) were assessed (Table 2). To compare the anti-peptide antibodies on an equal basis, immune mouse ascites fluids (MAFs) were purified by elution from protein A columns and standardized to

1 mg/ml and examined by ELISA. The reactivities of the purified Igs were not appreciably different from crude MAFs suggesting that binding to virus antigen or peptide was related to the original strength of the MAF and was not affected by increased/decreased affinity of the antibody to the peptide.

In addition to testing each of the anti-peptide antibodies individually, we attempted to reconstitute antigenic binding sites by mixing the antibodies together (Table 3). Seven anti-peptide antibodies were mixed in various combinations and each tested for binding to antigen, for ability to neutralize virus and for mediating enhanced virus growth. Binding of MAFs, 1 μ g and 10 μ g of anti-peptide antibodies to DEN-2 Jamaica virus antigen were examined by ELISA, and these results reflect original MAF titers. HL-CZ cells were infected with DEN-1 16681 virus at MOI of 10^5 . Where the positive ADE and background culture controls cells met our acceptance criteria, the enhanced virus yields in the presence of 1 μ g of anti-peptide antibodies was not consistent (Table 3). Neutralization activity of the anti-peptide antibodies against DEN-2 16681 virus was examined. One μ g of an antibody was mixed with 1000 pfu of virus and incubated at 37 C for 1 hour. The surviving virus was ascertained by testing the virus/Ab mixes in the BHK-21 plaque assay (16) and the results reported as percentage of reduction of input virus (Table 3). Both anti-peptide mix 21 (antibodies to peptides 06, 240, 274, 17 and 361) and mix 22 (anti-peptides 240, 274, 17, and 361) neutralized 53% of the input virus, and anti-peptide mix 42 (antibodies to peptides 240 and 274) neutralized 100% of the input virus.

Cloning and sequencing the nucleotides encoding the non-structural DEN-1 CV1636/77 genes. The genome encoding the structural genes of DEN-1 CV1636/77 have been previously published (3). Last year we completed the nucleotide sequences encompassing NS4a, NS4b, and NS5 genomic regions of DEN-1 CV1636/77 and compared the results with the published sequences of DEN-2 (5), DEN-3 (18), and DEN-4 (15). We have completed the sequencing of the rest of the non-structural nucleotide regions for NS1, NS2a, NS2b, NS3 and the final 800 base pair sequence of the 3'-end of the viral RNA (Figure 1).

The similarity of the non-structural gene regions between the 4 DEN viruses are summarized in Figure 2. DEN-1, DEN-2, and DEN-3 share between 63%-68% similarity by nucleotide sequence comparison and 65%-78% similarity by their deduced amino acid sequences over each of the non-structural gene regions. DEN-1 and DEN-4 however are very similar in NS3, NS4a, and NS4b regions (95%-98%); this is contrasted by a comparison of DEN-1 and DEN-4 over the NS5 region where similarity extends to only 78%. When the combined nucleotide and deduced amino acid sequences over NS3, NS4a, NS4b, and NS5 regions are examined, the similarity of 90% remains between DEN-1 and DEN-4 (Figure 3,4).

DISCUSSION

Studies to identify genomic correlates of DHF/DSS have primarily depended mouse, monkey and other laboratory experiments. Animals infected with DEN will respond by seroconversion to the infected virus but do not develop DHF/DSS. Therefore most disease parameters of infected humans are based on clinical observations, and epidemiological assessments. The availability of genomic sequences of flavi- and dengue viruses, the synthesis of peptides corresponding to deduced amino acid sequences, and the development of molecular techniques, make it possible to begin studies to correlate biological activities with genomic variation.

Relevance of epitope mapping using anti-peptide antibodies. With the standardized ADE assay, we have been able to examine divergent aspects of the roles of antibody, virus and host cells. From these studies, we could determine that each component share roles in virus replication and that the ADE system developed could isolate many of these factors for further examination. In our attempts to identify the genomic regions that encode antigenic epitopes involved in biological responses using anti-peptide antibodies, we could identify the epitopes that mediate neutralization of the virus. However, the enhancing activity could not be located within a specific region using the anti-peptide antibodies. This does not mean ADE activity cannot be found, the non-or broad reactivity may only be a matter of using sub-optimal antibody concentrations, the inappropriate mix of the anti-peptides, the virus strain variability or the susceptibility of the host cell stage to virus replication. It is likely that in using anti-peptides to map strategic epitopes, a reactive result implies reconstitution of epitopes, whereas non-reactivity implies only that epitopes were not reconstituted.

Using anti-peptide sera directed against selected DEN-2 E glycoprotein regions, we have been able to demonstrate that some of the E regions will elicit antibody that will mediate enhanced virus replication, neutralization and enhancement, and neutralization alone. Though this series of experiments need to be repeated with other antibody mixes and other DEN viruses, the neutralization epitope defined by amino acids 240-274 is the first direct association of specific E-glycoprotein regions with biological functions.

Analyses of the genetic relatedness of DEN viruses. The similarity of the non-structural genomic sequences of DEN-1 and DEN-4 viruses was unexpected. Published sequences of NS regions of DEN-2 and DEN-3 viruses led us to expect only 63%-68% homology among the DEN viruses. DEN-1 and DEN-4 viruses, however, appeared to be nearly identical from NS1 through NS5 and again at the 3'-end, suggesting that there may be a double-crossover genetic recombination. To preclude that possibility that the DEN stock cultures may have been contaminated with one or the other viruses, we plaque-picked purified virus from our CV1636/77 stock and found that they all

contained the same characteristics (data not shown). In addition, we are examining, by PCR amplification and sequencing, of other DEN-1 and DEN-4 strains in the 3'-end region to analyze the relationship.

Future studies. During this study, we were not able to achieve all the goals set forth in the original proposal. We would liked to have been able to get anti-DEN-1-peptide serum to analyze and work as we did with DEN-2 peptides. However, we were delayed by the unexpected complication of the DEN-1 sequence homology with DEN-4 and felt that was important finding to follow-up and analyze. We are planning to do work on examining patient serums that would recognize DEN-2 peptide mix 240/274 and to identify whether this region of the E-glycoprotein is a useful diagnostic tool.

REFERENCES

1. Brandt WE. 1990. Development of dengue and Japanese encephalitis Vaccines. *J Infect Dis* **162**:577-83.
2. Brandt WE, McCown JM, Gentry MK, and Russell PK. 1982. Infection enhancement of dengue type 2 virus in the U937 human monocyte cell line by antibodies to flavivirus cross-reactive determinants. *Infect Immun* **36**:1036-41.
3. Chu MC, O'Rourke EJ, and Trent DW. 1989. Genetic relatedness among the structural genome of dengue-1 virus strains. *J Gen Virol* **70**:1701-1712.
4. Deubel V, Kinney RM, and Trent DW. 1986. Nucleotide sequence and deduced amino acid sequence of the structural proteins of dengue type 2, Jamaica genotype. *Virology* **155**:365-77.
5. Deubel V, Kinney RM, and Trent DW. 1988. Nucleotide sequence and deduced amino acid sequence of the non-structural proteins of dengue type 2 virus, Jamaican genotype: comparative analysis of the full-length genome. *Virology* **165**:234-44.
6. Gubler DJ, Reed D, Rosen L, and Hitchcock JG. 1978. Epidemiologic, clinical and virologic observations on dengue in the kingdom of Tonga. *Am J Trop Med Hyg* **27**:581.
7. Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez S, and Morier L. 1990. Dengue hemorrhagic fever in Cuba. 1981: a retrospective seroepidemiologic study. *Am J Trop Med Hyg* **42**:179-84.
8. Halstead SB. 1988. Pathogenesis of dengue: challenges to molecular biology. *Science* **239**:476-81.
9. Halstead SB, and O'Rourke EJ. 1977. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. *J Exp Med* **146**: 218-29.
10. Menchal EZ, Gentry MK, McCown JM, and Brandt WE. 1982. Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. *Am J Trop Med Hyg* **31**:830-6.
11. Kerschner JH, Vorndam AV, Monath TP, and Trent DW. 1986. Genetic and epidemiological studies of dengue type 2 viruses by hybridization using synthetic deoxyoligonucleotides as probes. *J Gen Virol* **67**:2645-61.
12. King SD, Rose E, Bancroft WH, McCown JM, Woodall J, and Sather G. 1979. The laboratory diagnosis of dengue in Jamaica, 1977. PAHO Scientific Publication 375:153-8.

13. Littaua R, Kurane I, and Ennis FA. 1990. Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. *J Immunol* **144**:3183-6.
14. Liu WT, Chen SC, Lee N, Tan SK, Liu SF, Dunn P and Chang KSS. 1989. Establishment and characterization of a cell line of monocytic origin, HL-CZ, from human leukemia. *J Biomed Lab Sci* **4**:284-92.
15. Mackow E, Makino Y, Zhao B., Zhang YM, Markoff L, Buckle-White A, Guiler M, Chanock R, and Lai CJ. 1987. The nucleotide sequence of dengue type 4 virus: analysis of genes coding for non-structural proteins. *Virology* **159**:217-28.
16. Morens DM, Halstead SB, Repik PM, Putvatana R, and Raybourne N. 1985. Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. *J Clin Microbiol* **22**:250-4.
17. Morens DM, Marchette NJ, Chu MC, Burke DS, and Halstead SB. Growth in human peripheral blood leukocytes of dengue type 2 isolates correlates with severe and mild dengue disease. *Am J Trop Med Hyg* 1991 (in press).
18. Osatomi K and Sumiyoshi H. 1990. Complete nucleotide sequence of dengue type 3 virus genome RNA. *Virology* **176**:643-7.
19. Roehrig JT, Johnson AJ, Hunt AR, Bolin RA, and Chu MC. 1990. Antibodies to dengue 2 Jamaica E-glycoprotein synthetic peptides identify antigenic conformation. *Virology* **177**:668-75.
20. Unkeless JC, Scigliano E, and Freedman VH. 1988. Structure and function of human and murine receptors for IgG. *Ann Rev Immunol* **6**:251-81.

Tables

- Table 1 Chi-square comparison of the relationship between rosette expression and virus replication in HL-CZ cells
- Table 2 Reactivity of the mouse ascites fluids obtained from mice immunized with DEN-2 E glycoprotein synthetic peptides
- Table 3 Mixtures of purified anti-DEN-2 synthetic peptide immunoglobulins and PRNT/ADE results

Figures

- Figure 1 Location of CV1636/77 clones sequenced and the diagram of the similar regions between DEN-1 and DEN-4.
- Figure 2 Percentage of homology of the non-structural region nucleotide and deduced amino acid sequences of DEN viruses.
- Figure 3 Comparison of the nucleotide sequences comprising the non-structural genome regions of DEN-1, DEN-2, DEN-3 and DEN-4 viruses.
- Figure 4 Comparison of the deduced amino acid sequences of the non-structural regions of the four DEN viruses.

TABLE 1

Chi-square comparison of the relationship between rosette expression and virus replication in HL-CZ cells

PFU VIRUS/% ROSETTE	> 20% ROSETTE	< 20% ROSETTE
> 10 ³ VIRUS/ML	6*	1
< 10 ³ VIRUS/ML	1	4

*p < 0.001

TABLE 2 REACTIVITY OF ANTI-PEPTIDE ANTIBODIES AGAINST HOMOLOGOUS PEPTIDE, DENGUE-2 AND DENGUE-1 VIRUSES

PEPTIDE ^a	ANTIGEN USED IN ELISA ^b		
	PEPTIDE	DENGUE-2	DENGUE-1
1-2*	6400	1280	320
35	102400	128000	4000
3-8/1	100	<10	<10
4-6	400	40	10
04*	1600	160	10
142*	3200	640	10
167*	100	10	<10
06*	25600	5120	40
240#	1600	1280	80
274*	100	10	<10
16*	800	160	80
17#	3200	160	<10
361*	12800	640	80
437*	3200	20	80
+control	--	>12800	>12800
-control	--	<10	<10

^a Roehrig et al (19).

^b Each well of the ELISA plates were coated with either 1 ug of peptide, or gradient-purified virus antigen. The antibody titers as reported as positive were adjusted by subtracting 2 standard-deviations above background reactions.

* Synthetic peptides which are distinct by deduced amino acid sequence from DEN-2 Jamaica.

Synthetic peptides that are not distinct from DEN-2 Jamaica virus (>90% homology) but are in the NT/ADE region mapped by anti-peptide antibodies.

TABLE 3 ANTIBODY-DEPENDENT ENHANCEMENT (ADE) AND PLAQUE REDUCTION NEUTRALIZATION (PRNT) RESULTS

ANTI-PEPTIDE ANTIBODIES 100 NG ^a									PRNT ^b		ADE ^c
1-2	35	3/8-1	4-6	06	240	274	17	361	DEN1	DEN2	pfu/ml
■									20	35	250
	■								15	41	< 7
		■							19	32	< 7
			■						24	35	< 7
				■					15	32	>8300
					■				24	31	280
						■			31	32	4600
							■		27	36	>8300
								■	28	46	< 7
■	■	■	■	■	■	■	■	■	32	38	< 7
	■								36	42	3700
		■							42	56	260
			■						36	42	1400
				■					22	53	400
					■				18	53	< 7
						■			38	40	< 7
							■		10	19	< 7
		■							28	54	< 7
			■						16	56	< 7
				■					4	38	1500
					■				8	35	4000
						■			4	32	4500
							■		35	100	800
			■						16	27	5500
				■					0	10	3600
4G2 MAb*, flavivirus group reactive									96	97	>8300
3H5 MAb*, dengue-2 specific									12	100	8300
Virus control@									0	0	< 7

Legend for TABLE 3

- Purified anti-DEN-2 peptide antibodies, used 100 ng of each anti-peptide in the mixes. Filled boxes indicate the anti-peptide serum used.
- PRNT by BHK-21 semi-micro assay. Average plaques of DEN virus in each 24-well = 26. Serum and virus were incubated at 37 C for 1 hour. Percentage of neutralization shown here. >50 % reduction shown in **bold face**.
- ADE assay with HL-CZ cells and MOI of 10^5 . Cells were infected and incubated for 4 days at 37 C in 5% CO₂. Virus replication was assessed by plaque titration in BHK-21 semi-micro assay. Results are the average of 3 experiments.
- * The amount of 4G2 used for PRNT = 10 ug, for ADE = 1 ug. 3H5 used for PRNT = 1 ug, for ADE = 100 ng.
- @ Virus control = only virus without antibody for PRNT and ADE.

ABSTRACT

ASTMH 1991

206 THE NON-STRUCTURAL GENOME OF DENGUE-1 VIRUS CV1636/77: COMPARISON OF THE NUCLEOTIDE AND DEDUCED AMINO ACID SEQUENCES WITH THE OTHER DENGUE SEROTYPES.

Chu MC, Putvatana R, and Trent DW. Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases, Centers for Disease Control, Ft. Collins, Colorado 80526

The determination of the entire nucleotide and deduced amino acid sequences of the DEN-1 Jamaica CV1636/77 virus together with the known sequences of DEN-2, DEN-3 and DEN-4 viruses provide a complete sequence database of the DEN serotype complex. We have previously presented analyses of the nucleotide sequences encoding the structural and the non-structural NS3-NS4-NS5 regions. Sequence analyses of the entire genomic RNA and cloned cDNA of DEN-1 reveal that the genomic RNA contains 10,641 nucleotides and encodes an open reading frame of 10,224 nucleotides that translate into 3408 amino acid residues. A comparison of the DEN-1 sequence with DEN-2 (Jamaica; Deubel et al., 1988), and DEN-3 (H87; Osatomi et al., 1990) reveal that the genomic sequences encoding the structural (C-prM-M-E) and some of the non-structural (NS1, NS3, and NS5) regions are conserved (>70% homology). The 3'non-coding regions of DEN-1, DEN-2, DEN-3, and DEN-4 (Dominica; Mackow et al., 1987) are of different nucleotide lengths comprising 387, 455, 448, and 385 base pairs respectively. The entire non-structural sequences for DEN-1 and DEN-4 share >90% identity. These results reveal a close evolutionary relationship between Caribbean DEN-1 and DEN-4 viruses which cannot be detected by conventional serological methods. Thus the sequence database of all the DEN virus serocomplex will be a useful tool in studying the genetic variation and evolution of these viruses.

Prepared for ASTMH 1991


ABSTRACT

Antibody-dependent enhancement (ADE) of dengue (DEN) virus infection in human mononuclear cells in vitro has been standardized using a human promonocytic cell line HL-CZ, purified monoclonal antibodies (MAbs), and select DEN viruses. Characterization of the Fc-receptors (FcRs) expressed on HL-CZ cells have indicated that subsets of FcR mediate ADE better than others. Using this standardized system, we have compared the ability of mouse anti-DEN 2 envelope (E) peptides to elicit virus neutralization and ADE. Peptides 1-2, 437 appear to elicit ADE activity in contrast to other peptides that appear to elicit neutralization but not ADE. Though these assays need to be repeated, it appears that differential functions may be attributed to particular E genomic regions. The comparison of the nucleotide sequences of DEN-1 RNA encoding the non-structural proteins to the other DEN sequences has revealed that DEN-4 and DEN-1 share > 90% similarity in NS3 and NS4a, 4b genome regions. DEN-3 and DEN-1 have a deletion in in NS5 that is conserved in other DEN-1 and DEN-3 isolates. These genomic sequence comparisons indicate that non-structural region differences need to be studied as well for our understanding of DEN replication and pathogenesis.

PUBLICATIONS

1. Chu MC, Huang GH, Collins ND, and Trent DW. An experimental model for analyzing antibody-dependent enhanced growth of dengue virus in human promonocytic HL-CZ cells. Submitted for publication.
2. Chu MC, Putvatana R, Huang GH, Roehrig JT, and Trent DW. Analyses of the reactivities of anti-dengue-2-E glycoprotein antibodies to dengue-1 and dengue-2 viruses. Manuscript in preparation.
3. Chu MC, Putvatana R, Repik P and Trent DW. Similarities of the dengue-1 CV1636/77 and dengue-4 Caribbean viruses: genomic sequence comparison and oligonucleotide fingerprinting. Manuscript in preparation.

DENGUE VIRUS GENOME ORGANIZATION



OVERLAPPING cDNA CLONES



REGIONS OF > 90% IDENTITY BETWEEN DEN-1 AND DEN-4

(MARKED CLOSED AREAS BETWEEN THE ARROWS)



FIGURE 1

COMPARISON OF THE NON-STRUCTURAL GENOME
 OF DENGUE-1 CV1636/77 WITH
 DEN-2, DEN-3, AND DEN-4

	DEN-2		DEN-3		DEN-4	
	NT	AA	NT	AA	NT	AA
NS1	68%	59%	69%	59%	97%	84%
NS2a	36%	34%	38%	39%	99%	98%
NS2B	59%	53%	59%	55%	98%	95%
NS3	69%	71%	70%	74%	98%	95%
NS4a	64%	68%	61%	65%	99%	95%
NS4B	68%	83%	69%	82%	98%	97%
NS5	70%	75%	71%	81%	73%	79%
3'-END	67%		72%		97%	

FIGURE 2

COMPARISON OF THE NS2a NUCLEOTIDE SEQUENCES OF DENGUE VIRUSES

NS2a

3484

DEN-1 GGA CAG GGC ACA UCA GAA ACU UUU UCU AUG GGU CUG UUG UGC CUG ACC UUG UUU GUG GAA
 DEN-2U .G CAG AUU .C .ACA C.A .A G.C ... G.A A.. G.A C.. .C C.. ...
 DEN-3 ..G AGU .A .AG GUG .C .AC .C A.AG.CU U.. G.A A.C C.C U.U ...
 DEN-4

3544

DEN-1 GAA UGC UUG AGG AGA AGA GUC ACU AGG AAA CAC AUG AUA UUA GUU GUG GUG AUC ACU CUU
 DEN-2 ... AUG C.CCC C.. .A GGA .C.U GCA ... C.G C.A .U .CA G.A U.. U..
 DEN-3 ..G GUG A.. .A G.. .A U.U GGG .AAU GC. .GG .U C.C U.. .G U..
 DEN-4

3604

DEN-1 UGU GCU AUC AUG CUG GGA GGC CUC ACA UGG AUG GAC UUA CUA CGA GCC CUC AUC AUG UUG
 DEN-2 GUG A.A U.G ..U ACT ..G AA. A.G UCC .UU .GA ... CUG GG. A.. .UG A.G G.U ... G..
 DEN-3 GUG CUC C.. C.. UCA ..G CAA A.AGA .G. A.G GCG .AC A.AA ... A.U
 DEN-4U

3664

DEN-1 GGG GAC ACU AUG UCU GGU AGA AUA GGA GGA CAG AUG CAC CUA GCC AUC AUG GCA GUG UUC
 DEN-2 ..C .CU ..C ... A.G .A. GACU ATG GGA G.G ACU UAU CUU GC. C.A CU. .CA GCU
 DEN-3 ... UC. .AC GCCACG ..G ATG GGC C.. ACU UAC CUA GCU C.A AUU .CA ACA
 DEN-4

3724

DEN-1 AAG AUG UCA CCA GGA UAC GUG GUG GGU GUG UUA AGG AAA CUC ACU UCA AGA GAG ACA
 DEN-2 UUC .AA UU AG. CC. ACT U.U GCA .C. .GA C.A C.C UU. .G. AAA CUG ACC UCC A.. GA.
 DEN-3 UUU .AA AUU .AG CC. .U. U.. GCU UUG .GA ..C CU. .GG AAA CUG AC. UCU AGA GA.
 DEN-4A

3784

DEN-1 GCA CUA AUG GUA AUA GGA AUG GCC AUG ACA ACG GUG CUU UCA AUU CCA CAU GAC CCU AUG
 DEN-2 UU. A.GCC .CC AU. GGA AUC GCA CUC CUU UCC .AA AGC .CC AU. .CA ..G A.C ..U
 DEN-3 AAU U.. U.. C.G GG. .UU GG. UUG GCC .UG G.A .CA ACG .U. CGA .UG .CA ..G GAC ..U
 DEN-4

3844

DEN-1 GAA CUC AUU GAU GGA AUA UCA CUG GGA CUA AUU UUG CUA AAA AUA GUA ACA CAG UUU GAC
 DEN-2 CUU GAA C.G AC. .AU GCG .U. GCC CUG GGC ..G A.. G.C CTC .A. A.. GUG AGA AA. AUG
 DEN-3AA ..G .CG AAU GG. AUU GCU UUG GGG C.C A.. GCU CUU .A. C.G .U. ACA CAA UUU
 DEN-4AG.

DEN-1 AAC ACC CAA GUG GGA ACC UUA GCU CUU UCC UUG ACU UUC AUA AGA UCA ACA AUG CCA UUG
DEN-2 G.A .AG U.C CAA UUG G.A G.G A.. A.C AUG GCU .UC C.G UGU GUC C.. .AU GCA GUG A.A
DEN-3 G.A ..A U.C CAA CU. UGG ACG ..A U.A GUU .CC CUA ACG UGU UC. AAUU UUC AC.
DEN-4G
3964
DEN-1 GUC AUG GCU UGG AGG ACC AUU AUG GCU GUG UGU UUU GUG GUC ACA CUC AUU CCU UUG UGC
DEN-2 U.G CAA AAC GCA U.. .AG G.G .GU UGC ACA A.A ..G .CA .CG GUG UC. G.. U.. CCA CUG
DEN-3 U.G .CU .U. GCC U.. .GA .CA GCC A.. C.. A.U ..A .CC .GA .UU GCG C.. UUG CCA GUG
DEN-4
4024
DEN-1 AGG ACA AGC UGU CUU CAA AAA CAG UCU CAU UGG GUA GAA AUA ACA GCA CUC AUC CUA GGA
DEN-2 CUC UU. .CA .CC UCA ..G C.G A.A G.G G.. ... A.. CC. C.G G.. UUG ACG ..A AA. ..U
DEN-3 U.C CAG UCU .CG AGC AUG .GG A.A A.A G.. ... C.C CC. ..G ..U .UG GCA GCU A.G ...
DEN-4
4084
DEN-1 GCC CAA GCU CUG CCA GTG UAC CUA AUG ACU CUU AUG AAA GGA GCC UCA AGA AGA
DEN-2 CU. A.U CCA ACA G.C A.U .UUC. .C ... UC. .G. ACC AG. AAG .A. .AG
DEN-3 .UU .C. C.C ..A ... C.U UUU A.U U.C .G. ..G .AA G.U AC. CU. AA. ..G ...
DEN-4

COMPARISON OF THE NS4a NUCLEOTIDE SEQUENCES OF DENGUE VIRUSES

NS4a

	6382	AGU AUA ACU CUC GAC AUC CUA ACA GAG AUA GCC AGU UUG CCA ACU UAC CUU UCC UCU AGG
DEN-1		UC. U.G .C .G A. C.A AUCA .G .GU .G C.AU. ATG A.U CAG .A.
DEN-2		UCA .C G.C .U .U C.U G.GA .A .GA .A G. .U UCA C. .U.A G. .CAC .A
DEN-3	
DEN-4	
	6442	GCC AAG CUC GCC CUU GAU AAC AUA GUC AUG CUC CAC ACA ACA GAA AGA GGA GGG AGG GCC
DEN-1		.A .GA GA. .A .G .CU. .CU G. .G .U .C G.U .G GC. .U .AG
DEN-2		A.G .GA AA. . . .G .C .U U.G .GGCAU .C .U
DEN-3	
DEN-4	
	6502	UAU CUU CAC GCC CUG AAC GAA CUU CCG GAG UCA CUG GAA ACA CUC AUG CUU GUA GCU UUA
DEN-1		.C AA. .U .U .C .GUGA.CG C.U U.A C.G ACA C.C
DEN-2		.C AGG .U .A G. .G.GA .A .A A.G A.U.A .C C.G .GA C.G
DEN-3	
DEN-4		.AAA.
	6562	CUA GGU GCU AUG ACA GCA GGU AUC UUC CUG UUU UUC AUG CAA GGG AAA GGA AUA GGG AAA
DEN-1		.G .CC A.A G. . . .G. .AU.A .C .AAGC .AUG
DEN-2		A.G AUC UUG U.AGU .A GCA A.G .C .C .G .A UC. .UG .U .A .G
DEN-3	
DEN-4	C
	6622	UUG UCA AUG GGU UUG AUA ACC AUU GCG GUG GCU AGU GGC UUG CUC UGG GUA GCA GAA AUU
DEN-1		A. .A.C C. .A A. .UGU UG. .A AUC AC.AU. C.C .AUAUC.G .A
DEN-2		ACUA .A C.C .U UGU G.A AUU .CU U.C .CA. .U.AA.G .U .U G.C
DEN-3	
DEN-4	
	6682	CAA CCC CAG UGG AUA GCG GCC UCA AUC AUA CUA GAG UUU UUU CGC AUG GUA CUG UUG AUA
DEN-1		. . .A .CA .UAGU. .A .UC.C .U
DEN-2		.C .U. .ACTCG G.U .A G.C .GAUGG U. .C.C . . .
DEN-3	
DEN-4	
	6742	CCG GAA CCA GAA AAA CAA AGG ACC CCA CAA GAC AAU CAA UUG AUG UAC GUC AUA UUG ACC
DEN-1		.AG .A .A .CCU. G.C A.A G. .
DEN-2		.AG .G .A .U .CCC.C GCA .UG.A A.GG.
DEN-3	
DEN-4	

6802 AUU CUC ACC AUC AUU GGU CUA AUA GCA GCC
 ..C ..: ..A G.G G.G .CC GC. .CC AUG ..A
 ..A ..U ..A U.G GC. .CA A.. G.. ..G ...
: ..: ..: ..: ..: ..: ..: ..: ..:

DEN-1
 DEN-2
 DEN-3
 DEN-4

6831

DEN-1 GGU GAG UCC UCU CCG AAU CCA ACU AUA GAA GAA GGA AGA ACG UUA CGU GUU CUA AAG AUG GUG
 DEN-2 .G . . .G . .A . .A . .C . .GCA . . . C . .A C.C AGA . .C . .C . .C U.A . .A
 DEN-3 .A . .A . .U . .A . .A . .GCA G.GA.CC A . .A . .C U.GU
 DEN-4 .GAU.UAGAAU.G
8068
 DEN-1 GAA CCA UGG CUC AGA GGA AAC CAA UUC UGC AUA AAA AUC CUA AAU CCU UAC AUG CCA AGU
 DEN-2 . . . AAU . . . U.G . .AC AAU . . . ACCUG G.U . .C . .A . .UC UCA
 DEN-3A . .A . .AACGUG.A U.G . .C . .AC.
 DEN-4 .GTCT TC. . .A CCU G. . . .GGU . .C . .CCA
8128
 DEN-1 GUG GUA GAA ACU CUG GAG CAA AUG CAA AGA AAA CAU GGA GGG AUG CUA GUG CGA AAC CCA CUC
 DEN-2 . .C A. . . .AA A. . . .A AC. C.AGUA GCC U. . . .A.G . .U
 DEN-3 . . . A.U . .G CAC U.A . .A AG. C.AAUA . . .U
 DEN-4 . .C A. . . .GAGACGAC . .U . .C A. . . .UG. . .G . .G
8191
 DEN-1 UCA AGA AAU UCC ACC CAU GAA AUG UUA UGG GUU UCA UGU GGA ACA GGA AAC AUT GUG UCG GCA
 DEN-2 . . . C. . . .CAGGA . .C AA. .C. U.C . .GAA U.
 DEN-3 . . . C. . . .CCA . .A . .C AA. . .UCC . .C . .U U.
 DEN-4 . .C . .G . .CGG . .A .CG U.GAGC U.U
8254
 DEN-1 GUG AAC AUG ACA UCC AGA AUG UUA CUG AAU CGA UUC ACA AUG GCU CAC AGG AAG CCA ACA UAU
 DEN-2U.U . .A . .GG A.U . .C A.AAAA. . .A G.C . .C . .C
 DEN-3 . .CGU.U. . . .CC A.A.AGA . .C . .C AUA
 DEN-4CAA . .AGG U.C A.GCA AGG . .UA . .C . .U
8317
 DEN-1 GAA AGA GAC GUG GAC UUA GGC GCU GGA ACA AGA CAU GUG GCA GUG GAA CCA GAG GUA GCC AAC
 DEN-2 . .G .C. . .U . .UC. . . .A AGCC C.C A.C A.U .G. A.UAGUA. . .C.A . .U
 DEN-3 . .G .A. . .UUA . .A . .C C.AC AAU .C.A AC. C.
 DEN-4 . .G .AGA . .U C.U . .GAGAG. . .C U.C ACUA. .A AA. C.A G. . . .
8380
 DEN-1 CUA GAU AUC AUU GGC CAG AGG AUA ACA UGG GCC UAU CAU GGA UCA UAU GAG GUC AAG CCA UCA GGA
 DEN-2C . .A . .A . .A . .AAG C.A . .G . .U G.A A.UC
 DEN-3 A.GG . . .G . .G G.A . .AA.A .GG . .CG.G . .G . .U .GUC
 DEN-4 A.G ACAG . .G AGAC.U C. . .CGA U.G C. . .G.A . .G . .C . .A GA. . .C
8443
 DEN-1 GAU GAA GAC AAU CCA UAC AAA ACA UGG GCC UAU CAU GGA UCA UAU GAG GUC AAG CCA UCA GGA
 DEN-2 . .C C. . . .C.CGGU . .CC AGCA ACA . .A .A.U
 DEN-3U . .AUGGU . .CCA . .A . .G.C A. . . .C
 DEN-4C.G . .A . .CGCAGCA CCU CCU U.G A.C

DEN-1 GGU GUC GAC AGG CUG AAA AUG GCA AUU AGC GGA GAU GUG GUG AAA CCA AUU AGU
DEN-2 .G CGU .AA UC. . . .C .C .UU .AU U.A GA.
DEN-3 .A .G .GU.AC .CGC .AC GAC
DEN-4U.A .G .GC .UCCGC C.A GA.
9577
DEN-1 GAC AGG UUC GCA ACA GCC UUA AUA GCU CUG AAU GAC AUG GGA AAA GUA AGA AAA GAC AUA CCG
DEN-2A .UGU .UC. . . .AU .GUAA
DEN-3AC .AUC.G C.UC .UG .UGU
DEN-4U .GC .U U. . . .C.C C.C UUC U. . . .C C.GG .GU

9640
DEN-1 CAG UGG GAA CCU UCA AAA GGA UGG AAU GAC UGG CAG CAA GUG CCU UUC UCA CAC CAU UUC
DEN-2AG.C .UACAU
DEN-3C.G .AGC. . . .UA .GCCC .U
DEN-4AA .U .GA .AA G.G .UUC G.CC C.U

9703
DEN-1 CAC CAG CUG AUC AUG AAG GAU GGG AGG GAA AUA GUG GUG CCA UGC CGC AAC CAA GAU GAA CUU
DEN-2U G. . . .U.A G. . . .AU C.C .UG C.C .AA.AG
DEN-3U G.A U.AA .A .G U.G .A .UA.A CC. . . .GCA
DEN-4A. . . .ACC U.UC C.C UC. C. . . .U .UU A.AGGG

9766
DEN-1 GUG GCA AGG GCU AGA GUA UCA CAA GGC GCC GGA UGG AGC CUG AGA GAA ACU GCU UGC CUA GGC
DEN-2 A.U .GU .AC C. . . .A.UC .GAGUCU U. . . .AGGCU U.GG
DEN-3 A.A .G. .AGA.C .UA .AA.G
DEN-4 A.A .G. .AA .CA.C .GGA .UU.AACGG

9829
DEN-1 AAG UCA UAU GCA CAA AUG UGG CAG CUG AUG UAC UUC CAC AGG AGA GAC CUG AGA CUA GCG GCU
DEN-2UC .CACCA C.CGGA
DEN-3A G.CC .UACUCUUUA U.C
DEN-4A G.UCC .GUCGUA .GC.U U. . . .C U.C

9892
DEN-1 AAU GCU AUC UGU UCA GCC GUC CCA GUU GAU UGG GUC CCA ACC AGC CGC ACA ACC UGG UCA AUC
DEN-2UC .GAG UCA C.A .UACA
DEN-3CAA .AC C.CGA.AAUU
DEN-4 .UGCACA .UACGAU.UA .AA

9955
DEN-1 CAU GCC CAC CAA UGG AUG ACA GAA GAC AUG UUA UCA GUG UGG AAU AGG GUU UGG AUA
DEN-2CU A.GU G.G .GC.G G.CC
DEN-3UUGUC.U A.UCGG
DEN-4CUUGC .UC.C AA.CAG

DEN-1 CCCCCCAACAC AAAAACAGCAUAUUGACCGUGGAAAGACCAGAGAUCCUGCUGUCUCAAUCAUCCAGGCACAGA
 DEN-2A..A.....
 DEN-3GC.A.....
 DEN-4

3' end length

(387)
 (455)
 (448)
 (385)

10653

DEN-1 GCGCCGCAAGAUGGAUUGGUGUUGUUGAUCCAAACAGGUUCU
 DEN-2 A....AG..A....A.....C.....AU.....U
 DEN-3 A....AG..A....A.....C.C....AU.....U
 DEN-4

COMAPRISON OF THE DEDUCED NS2a AND NS2B AMINO ACID SEQUENCES OF DENGUE VIRUSES

NS2a

DEN-1 GQGTSETFSM GLLCLTLFVE ECLRRRVTRK HMILVVVITL CAIILGGLTW MDLLRALIML
 DEN-2 .H.QIDN..L ..GMA..L. .M..T..GT. .A..L.AVSF VTL.T.NMSF R..G.VMV.V
 DEN-3 ...KVDN.T. .V...AILF. .VM.GKFGK. ...AG.LF.F VLLLS.QI.. RGMHT...I
 DEN-4 S.....

DEN-1 GDTMSGRIGG QIH LAIMAV FKMSPGYVLG VFLRKLTSRE TALMVIGMAM TTVLSIPHDL
 DEN-2 .A..TDD..M GVTY..LL.A ..VR.TFAA. LL.....K. LMMAT..I.L LSQST..ETI
 DEN-3 .SNA.D.M.M GLTY..LI.T ..IQ.FLA.. F.....NL.LGV.L.. AAT.RL.E.I
 DEN-4 R.....

DEN-1 MELIDGISG LILLKIVTQF DNTQVGTLLAL SLTFIRSTMP LVMAWRTIMA VLFVVTLIPL
 DEN-2 L..T.ALA.. MMV....RNM EKY.LAVTIM AILCVPNAVI .QN...KVSCT I.AA.SVS..
 DEN-3 EQMAN..A.. .MA..LI... ETY.LW.ALV ...CSNTIFT .TV....ATL I.AGIS.L.V
 DEN-4 S..... D.....

NS2B

DEN-1 CRTSCLQKQS HWVEITALIL GAQALPVYLM TLMKGASRRS WLLNEGIMAV GLVSLIGSAL
 DEN-2 LL..SQ..AD .IPLALTIK .LNPTAIF.T ...RTSKK.. P...A.... M..I.A.S.
 DEN-3 .QS.SMR.TD .LPM.VAAM .VPP..LFIF S.KDTLK... P.....V.... I.A.S.
 DEN-4 A..... P.....

DEN-1 LKNDLPLASP MVAGGLLLAA YMSGSSADL SLEKAANVQW DEMADITGSS PIIEVKQDED
 DEN-2I.MTG. L.....TVC ..LT.R.... E..R..D.K. EDQ.EIS... ..LSITIS..
 DEN-3 ...V.M.G. L.....I.C ..IT.T.... TV.....D.T. E.E.EQ..V. HNLMITV.D.
 DEN-4 ...CV...G.M.....

DEN-1 GSFSIRDVEE TSMITLLVKL DLITVSGLYP LAIPVTMTLW YMWQVKTQR
 DEN-2 ..M..KNE.. EQTL.I.IRT G.LVI..VF. VS..I.AAA. .L.E..K..
 DEN-3 .TMR.K.D.T ENIL.V.L.T A.LI...IF. YS..A..LV. HT..KQ...
 DEN-4 N..... A.....

COMPARISON OF THE DEDUCED NS3 AMINO ACID SEQUENCE OF DENGUE VIRUSES

	NS3	
DEN-1	SGSLWDVPSP AATQKAALSE GYRIMQRGL FRKTQVGVGI HMEGVFHTMW HVTRGSSVICH	
DEN-2	A.V..... PPVG..E.ED .A...K...I LGYS.I.A.V YKE.T..... .A.LM.	
DEN-3	.V..... PET...E.E.K.Q.I .G.....V QKE.....A.LT.	
DEN-4	.A..... .K..... .G.....	
DEN-1	ETGRLEPSWA DVRNDMISYG GGWRIGDKWD KEEDVQVLAI EPRKNPKHVQ TKPGLFKTLT	
DEN-2	KGK.I.... .KK.L.... .K.EGE.K EG.E...L .G...RA.N.	
DEN-3	NGK....N.. S.KK.L.... .SAQ.Q .G.E..I.V .F...NF. .M..I.Q.T.	
DEN-4G..... .S.....	
DEN-1	GGIGAVTLDF KPSTSGSPII NRKGKVIPLY GNGVTKSGD YVSAITQAEER IGEPTYEVDE	
DEN-2	.T...S... S.G.....V D....V... ..R..A ...A.T.K SI.DNP.IED	
DEN-3	.E...IA... .G..... .E..V... ..N.G ..G.A.TNA EPDGPPTPEL.	
DEN-4	.E..... .G.....	
DEN-1	DI FRKKRLT IMDLHPGAGK TKRILPSIVR EALKRRLRNL ILAPTR AA EMEEALRGLP	
DEN-2Y.A... .I.G.T.VV..	
DEN-3	EEM.K.RN..S... .KY.A... .I.....T.VV.. .PMK...	
DEN-4I.....T.VV..	
DEN-1	IRYQTPAVKS EHTGREIVDL MCHATFTTRL LSSTRVSNYN LIVMDEAHFT DPSSVAARGY	
DEN-2IRAM... .PV..P... .I..... .A.I.....	
DEN-3T.T.M... .PV..P... .I..... S.A.I.....	
DEN-4P.....	
DEN-1	ISTRVEMGEA AAIFMTATPP GATDPFPQSN SPIEDIEREI PERSWDTGFD WITDYQGKTV	
DEN-2G..... .SR..... .A.M.E.... .NS.HE .V..FK....	
DEN-3G..... .TA.A.... .A.Q.E.E.D.NS.NE ..FV....	
DEN-4	
DEN-1	WFVPSIKAGN DIANCLRKSG KKVQLSRKT FDTEYPKTKL TDWDFVVTID ISEMGANFRA	
DEN-2A....N.S.V..RA N.....K.	
DEN-3V.....N.Q.... N.....I.	
DEN-4	

DEN-1 GRVIDPRRCL KPVILTCGPE RVILAGPIPV TPASAAQRRG RIGRNPAQED DQYVFSGDPL
DEN-2 E.....MD.E.M... .HS..... .KN.N ...IYM.E..
DEN-3 D.....MM... .V..... .V....QK.N ...I.M.Q..
DEN-4P.....

DEN-1 KNDEDHAHWT EAKMLLDNIY TPEGIPTLF GPERKTQAI DGEFRLRGEQ RKTFFVELMRR
DEN-2 E.....C...KNSM. E.....VD.. .Y.....AD...
DEN-3 NK.....NNA.. E.....SA.. .Y..K.DS
DEN-4NNA.. E.....SA.. .Y..K.DSD...

DEN-1 GDLPVWLSYK VASAGISYKD REWCFTGERN NQILEENMEV EIWTREGEKK KL PRWLDAR
DEN-2A.R ..AE..N.A. .R...D.IK.V... .K...R. ..K.....
DEN-3AH.E..K.T. .K...D... ..D... .K...R.R.....
DEN-4NNA.. E.....SA.. .Y..K.DSD...

DEN-1 VYSCPLALKD FKEFASGRK
DEN-2 I..D.....EA...
DEN-3 T..D.....E ..D..A...
DEN-4 ..A..M.....

COMPARISON OF THE DEDUCED NS4a AND NS4B AMINO ACID SEQUENCES OF DENGUE VIRUSES

NS4a

DEN-1 SITLDILTEI ASLPTYLSSR AKLALDNIVM LHTTERGGRA YLHALNELPE SLETLMLVAL
 DEN-2 .L..NLI..M GR...FMTQK .RD...ALV ...A.A... ..S... T...L.LT.
 DEN-3 .A..LV... GRV.SH.AH. TRN...L... ..S.H... ..R..VE... TM...L.LG.
 DEN-4 Q.....T.....

DEN-1 LGAMTAGIFL FFMQKGIGK LSMGLITIAV ASGLLWVAEI QPQWIAASII LEFFRMVLLI
 DEN-2 .ATV.G... .L.S... MTL.MCC.IT .I...Y.Q. ..H..... ..LI....
 DEN-3 MILL.G.AM. .LIS..... T.I...CVIA S.M.M.DV PL...SA.VM.....
 DEN-4L.....

DEN-1 PEPEKQRTPO DNQLIYVILT ILTIIGLIAA NEMGLIEKTK TDFGFYQVKT ETTILDV
 DEN-2T...IA ...VVAATM. ..N.FL... K.L.LGSIT. QESESN...I
 DEN-3A..VIG ...LAAIV... ..L.TTH R.L.MSKEPG VVSP.SY...
 DEN-4

DEN-1 DLRPASAWTL YAVATTILTP MLRHTIENTS ANLSLAAIAN QAAVLMGLGK GWPLHRMDLG
 DEN-2FV... ..S...S. V.V..T... ..T..... ..SKIHI.
 DEN-3V... ..ST..V..... ..V.....D.ISK....
 DEN-4

NS4B

DEN-1 VPLLAMGCYS QVNPTTLTAS LGMLLVHYAI IGPGLQAKAT REAQKRTAAG IMKNPTVDFI
 DEN-2I.... ..I...A .LL.VA... ..A... ..G.
 DEN-3L... ..I.A VLL.VT... ..G.
 DEN-4A.. .V..... ..I..G.

DEN-1 TVIDLEPISY DPKFEKQLGQ VMLLVLCAGQ LLLMRITWAF CEVLTLATGP ILTLWEGNPG
 DEN-2P.I..VT. V.M.....L ..A..... ..S.....
 DEN-3 MT...D.VI. .S..... ..S..L ..T.....S..
 DEN-4

DEN-1 RFWNTTIAVS YANIFRGSYL AGAGLAFSLI KNAQTPRR
 DEN-2H..... ..L..IM ..TTNT..
 DEN-3 K.....M..... ..L.IM .SVG.GK.
 DEN-4 T.....

COMPARISON OF THE DEDUCED NS5 AMINO ACID SEQUENCE OF DENGUE VIRUSES

	NS5	
DEN-1	GTGTTGETLG EKWKTQLNQL SKSEFNTRYK SGIMEVDRSE AKEGLKRGET TKHAVSRGTA	
DEN-2	...NI... SR..A. GE...QI..K ..Q...TL ..I... D.....S.	
DEN-3	...SQ... ..KK... ..RK..DL..K ..T...T.I.H.....S.	
DEN-4R...S. DRK..EE... ..L...T. ..SA..D.SK M.....SS	
DEN-1	KLRWFVERNL VKPEGKVIDL GCGRGWSY CAGLKKVTEV KGYTKGGPGH EEEIPMATYG	
DEN-2M I.....VC.G...N.R.. ..L.....HS...	
DEN-3M I...R..... ..M.TL.N... ..R.....V..S...	
DEN-4	I..I...GM .K.K.E.V.. ..M.TL.N... ..R.....V..S...	
DEN-1	WNLVKLHSGK DVFFTPPEK CTLLCDIGES SPNPTIEGR TLRVLKMVEP WLRGN QFCI	
DEN-2	...R.Q..V C.....I..... ..A.. I...NL..N ..NN.T....	
DEN-3Y..... ..S.V..S.KN.	
DEN-4	...Y.....V L.YK.T.QV D.....S..... ..SSKPE.W.	
DEN-1	KILNPYMPV VETLEQMQRK HGGMLVRNPL SRNSTHEMYW VSCGTGNIVS AVNMTSRMLL	
DEN-2	.VS..... I.KM.TL... Y.A..... ..NAS..... S..HI..H.I	
DEN-3	.V..... T. I.H..RL... ..N..C... ..I.N..... S...V..L..	
DEN-4	.V..... T. I.E..KL... ..N..C... ..GAS..... S.I..K...	
DEN-1	NRFTMAHRKP TYERDVDLGA GRRHVAVEPE VANLDIGQR IENIKNEHKS TWHYDEDNPNY	
DEN-2	...K..KA ..T.....S .T.NIGI.S. IP...T.K.Q..ET S...Q....	
DEN-3	...R... I.K..... ..T...NA... TP.M.V..E. .KR..E..S.DE...	
DEN-4	...TR... ..K..... ..T.S.ST.TK KPDMIISGR. LQRLQE...EQ....	
DEN-1	KTWAYHGSYE VKPSGSASSM VNGVVRLLTK PWDVIPMTQ IAMTDTTPFG QORVFKEKVD	
DEN-2T.QT..... ..V..... N.H.....	
DEN-3AT..... I...K... ..V..... M.....	
DEN-4	R..... PPST..P... ..K..... ..C..... L.V..AIH.. ..	
DEN-1	TRTPRAKRGT AQIMEVTAKW LWGFLSRNKK PRICTREEFT RKVRSNAAIG AVFVDENQWN	
DEN-2	...QEP.E.. KKL.LI..E. ..KE.GKK.T .M..... ..L... I.I..NK.K	
DEN-3	...PMP.. RKV..I..E. ..RT.G...R .L..... K...T...M. ...TE...D	
DEN-4	...QP.P.. RMV.TT..N. ..AL.GKK.N .L.....I S..... R..QE.QG.T	

DEN-1	SAKEAVEDER	FWDLVHRERE	LHKQKCATC	VYNNMGKREK	KLGEFGKAKG	SRAIWYMWLG
DEN-2	..R.....S	..E.D..N	..LEC....E....
DEN-3	..RA.....E	..K.D...D	..L...GS.
DEN-4	..S.....S	..E.DK.A	..QE...ES.R....
DEN-1	ARGLEFEALG	FMNEDHWFSR	ENSLSGVEGE	GLHKLGYILR	DISKIPGGNM	YADDTAGWDT
DEN-2	..F.P....	..L.....	..G.....V.V...E..A.I.....
DEN-3	..F.....	..L.....	..Y.....A....
DEN-4	..F.....	..L.....G.	..W.....	..R.....E	E.D.KD.DL.
DEN-1	RITEDDLQNE	AKITDIMEPE	HALLATSIFK	LTYQNKVVTL	ORPAKNGTVM	DVISRRDQRG
DEN-2	..L..K..	EHV.NH.G.	.KK..EA...RV...	..TPR....	..I.....
DEN-3	..H..	E..QQ.D..	.RQ..NA...KV...	..TPK....	..I..K....
DEN-4DL..EQ.A.H	.KI..KA...FV L..TPR.A..	..I..KE...
DEN-1	SGQVGTGLN	TFTNMEVQLI	QROMESEGVIT	QDDMQNPKGL	KERVEKWSKE	CGVDRLLKRMMA
DEN-2G..G..IFK	SIQHLLTVEE	IAVON .LAR	V..KE..S...
DEN-3AG..	..G..LS	KA.LE..HP.	EKKITQ.LET	K..E.....
DEN-4S	..A.....L..
DEN-1	ISADDCVVKP	LDERFGTSL	FLNDMGKVRK	DIPQWEPKSG	WNDWQQVPFC	SHHFHQLIMK
DEN-2	..G.....	..D..ASA.T	A.....Q...R.T.....	..I..E.V..
DEN-3I.D..ANA..	A.....Q...	..H.....E....
DEN-4	..G.....K..E....	A..L.KTF..
DEN-1	DGREIVVPCR	NQDELVARAR	VSQGAGWSLR	ETACLKGSYA	QMWQLMYFNR	RDLRLAANAI
DEN-2	..C.VL...IG...	I.....KT...H.
DEN-3	..KL...Q	P...IG...	I.....	..T...H.S...
DEN-4	..SL.....IG...	I.....A..	..S...H.M...
DEN-1	CSAVPVDWVP	TSRTTWSIHA	HHQWMTTEDM	LSVWNRVWIE	ENPWMEKTP	VHSWEEVPYL
DEN-2SH...	I.....	..K.E.N....	..A...K...QE.....
DEN-3H...T.....DTT..D....
DEN-4TE.F.K.....	..D.N.T....DI....
DEN-1	GKREDLWCGS	LIGL SSRAT	WDENIHTAIT	QVRNLIGKEE	YVDYMPVMKR	YSAPSESEGL
DEN-2Q....T...	..AK..Q...N	..S...H..	..T...S...	FRREE.EA...W
DEN-3Q....T...	..AQ..L...Q	..S...N..	..FL...R...	FRKEE...AIW
DEN-4T....	..AK.....

DEN-1 GGU GUC GAC AGG CUG AAA AGA AUG GCA AUU AGC GGA GAU GAU UGU GUG AAA CCA AUU AGU
DEN-2 ..G CGU ..A UC.C ..C ..U ..U ..AU ..A GA.
DEN-3 ..A ..G ..G ..U.AC ..C ..GC ..AC GAC
DEN-4 U.A ..G ..GC ..UCG ..C C.A GA.
9577
DEN-1 GAC AGG UUC GCA ACA GCC UUA AUA GCU CUG AAU GAC AUG GGA AAA GUA AGA AAA GAC AUA CCG
DEN-2A ..UGU ..UCAU ..GUAA
DEN-3AC ..AUC.G C.UC ..UG ..U ..GU
DEN-4U ..GC ..U U.. C.C C.C UUC U.. ..C C.GG ..GU
9640
DEN-1 CAG UGG GAA CCU UCA AAA GGA UGG AAU GAC UGG CAG CAA GUG CCU UUC UGU UCA CAC CAU UUC
DEN-2 ..AC.G ..AGC ..UACAUCU
DEN-3 ..AC.G ..AGC ..UA ..G ..CC ..CC ..U
DEN-4A ..U ..GA A..A G.G ..UC G.CC C.U
9703
DEN-1 CAC CAG CUG AUC AUG AAG GAU GGG AGG GAA AUA GUG GUG CCA UGC CGC AAC CAA GAU GAA CUU
DEN-2 ..U G.. U.A G..AU C.C ..UG C.C ..A ..CA.ACG
DEN-3 ..U G.A U..AA ..A A.G U.G ..A ..U ..CA.A CC. ..G ..CA
DEN-4A.. ACC U.UC C.C UC. C.. ..U ..UU A.AGG
9766
DEN-1 GUG GCA AGG GCU AGA GUA UCA CAA GGC GCC GGA UGG AGC CUG AGA GAA ACU GCU UGC CUA GGC
DEN-2 A.U ..GU ..A ..C C.. A.U ..C ..G ..AGUCU U.. ..AG ..G ..C ..U U.G ..G
DEN-3 A.A ..G. ..A ..GA.C ..UA ..A ..A.UA ..UG
DEN-4 A.A ..G. ..A ..CA.C ..G ..G ..A ..UU.AA ..CG
9829
DEN-1 AAG UCA UAU GCA CAA AUG UGG CAG CUG AUG UAC UUC CAC AGG AGA GAC CUG AGA CUA GCG GCU
DEN-2U ..C ..C ..UACCCA C..CGA
DEN-3 ..A G.C ..C ..UACU ..CU ..UAU ..UA U.C
DEN-4 ..A G.U ..C ..C ..GUCG ..UUA ..AG ..UC.U U.. ..C U.C
9892
DEN-1 AAU GCU AUC UGU UCA GCC GUC CCA GUU GAU UGG GUC CCA ACC AGC CGC ACA ACC UGG UCA AUC
DEN-2U ..C ..C ..G ..AG UCA C..UACC ..A
DEN-3 ..C ..C ..AA ..A ..AC C..GA.A ..G ..AU ..U
DEN-4 ..UG ..C ..A ..CA ..UACG ..AU.UA.AA
9955
DEN-1 CAU GCC CAC CAC CAA UGG AUG ACA ACA GAA GAC AUG UUA UCA GUG UGG AAU AGG GUU UGG AUA
DEN-2 ..C ..U A.G ..U G..GG ..GC.G G..CCC
DEN-3UU ..GUUC.U A.U ..CCG
DEN-4 ..C ..U ..UGC ..UC ..C AA.C ..C ..A ..GG

DEN-1	CCCCCCAAACAC	AAAAACAGCAUAUUGACGCGUGGAAAGACCAGAGAUCCUGUGUCUGCAACAUCAAUCCAGGCACAGA	
DEN-2A..ACU..G.....U.....	
DEN-3GC.A.G.....CU..G.....U.....	
DEN-4C.....	<u>3' end length</u>
		10653	
DEN-1	GCGCCGAAGAUGG	UUGUUGUUGAUCCAAACAGGUUCU	(387)
DEN-2	A...AG..A...	A.....C.....AU.....U	(455)
DEN-3	A...AG..A...	A.....C.C.....AU.....U	(448)
DEN-4U	(385)

COMPARISON OF THE DEDUCED NS1 AMINO ACID SEQUENCES OF DENGUE VIRUSES

NS1

DEN-1	DSGCVINWKG	KELKCGSGIF	VTNEVHTWTE	QYKFAQDSPK	RLSAAIGKAW	EEGVCGIRST
DEN-2	..VS..NI.DNPE..S	K.AS..Q..H	...I.....V	
DEN-3	.M.....VAT..AGN	
DEN-4	.M...VS.S.VDN.....PE..A	..AS..LN.H	KD.....	
DEN-1	TRLENVMWKQ	ITNELNYVLW	EGGHDLTVA	GDVKGVLTKG	KRALTPPVSD	LKYSWKTWVK
DEN-2P	..HI.S	NEVK..IMT	..CI..IMQA	..S.R.QPTE
DEN-3	..M..LL...	..A.....I..	..NDIK.....V	..CIT...EQ.	..T...QPMEL
DEN-4
DEN-1	AKIFTPEARNS	STFLIDGPD	SECPNERRAW	NSLEVEDYGF	GMFTTNIWMK	FREGSSEVCD
DEN-2	..MLST.SH.	Q.....E	A.....N	V.....I.L.	L..KQDVF..
DEN-3	..V.A.TQ.	..S.I.....S	..P...SAS	..VW.....	V.....L.	L..VYTQL..
DEN-4
DEN-1	HRMSAAIKD	QKAVHADMGY	WIESSKNQIW	QIEKASLIEV	KTCLWPKTHT	LWSNGVLESQ
DEN-2	SK.....	NR.....	..AL.D..	KM.....F...	..S.H...SE
DEN-3V	ER.....	..Q..GS	KL.....	..T...SD
DEN-4
DEN-1	MLIPKEYAGP	FSQHNYRQGY	ATQTVGPWHL	GKLEIDFGEC	PGTTVTIQED	CDHRGPSLRT
DEN-2	.I...NF...	V.....P..	H...A.....	..M..DF.	E.....VVT..	..GN.....
DEN-3SL...	I.....P..	H...A.....	..L..NY.	E.....V.S.N	..GT.....
DEN-4S
DEN-1	TTASGKLVTO	WCCRSCMTMP	LRFLGEDGCW	YGMEIRPLSE	KEENMVKSQV	TA
DEN-2I.EL..	..YR.....K.L.N.L.	..
DEN-3	..TV.....IHEL..	..YM.....IN.LA	S.
DEN-4A	MV.T

COMAPRISON OF THE DEDUCED NS2a AND NS2B AMINO ACID SEQUENCES OF DENGUE VIRUSES

NS2a

DEN-1 GQGTSEFMS GLLCLTLEVE ECLRRRVTRK HMILVVVITL CAIILGGLTW MDLLRALIML
 DEN-2 .H.QIDN..L ..GMA..L. .M..T..GT. .A..L.AVSF VTL.T.NMSF R..G.VMV.V
 DEN-3 ...KVDN.T. .V...AILF. .VM.GKFGK. ...AG.LF.F VLLLS.QI.. RGMHT...I
 DEN-4 S.....

DEN-1 GDTMSGRIGG QIH LAIMAV FKMSPGYVLG VFLRKLTSRE TALMVIGMAM TTVLSIPHDL
 DEN-2 .A..TDD..M GVTY..LL.A ..VR.TFAA. LL.....K. LMMAT..I.L LSQST..ETI
 DEN-3 .SNA.D.M.M GLTY..LI.T ..IQ.FLA.. F..... NL.LGV.L.. AAT.RL.E.I
 DEN-4 R.....

DEN-1 MELIDGISLG LILLKIVTQF DNTQVGTLLAL SLTFIRSTMP LVMAWRTIMA VLFVVTLIPL
 DEN-2 L..T.ALA.. MMV....RNM EKY.LAVTIM AILCVPNAVI .QN..KVSCT I.AA.SVS..
 DEN-3 EQMAN..A.. .MA..LI... ETY.LW.ALV ...CSNTIFT .TV.....ATL I.AGIS.L.V
 DEN-4 S..... D.....

NS2B

DEN-1 CRTSCLQKQS HWVEITALIL GAQALPVYLM TLMKGASRRS WLLNEGIMAV GLVSLGGSAL
 DEN-2 LL..SQ..AD .IPLALTIK .LNPTAIF.T ...RTSKK.. P...A.... M..I.A.S.
 DEN-3 .QS.SMR.TD .LPM.VAAM .VPP..LFIF S.KDTLK... P.....V... I.A.S.
 DEN-4 A..... P.....

DEN-1 LKNDLPLASP MVAGGLLLAA YMSGSSADL SLEKAANVQW DEMADITGSS PIIEVKQDED
 DEN-2I.MTG. L.....TVC ..LT.R.... E..R..D.K. EDQ.EIS... .LSITIS..
 DEN-3 ...V.M.G. L.....I.C ..IT.T.... TV.....D.T. E.E.EQ..V. HNLMITV.D.
 DEN-4 ...CV...G.M.....

DEN-1 GSFSIRDVEE TSMITLLVKL DLITVSGLYP LAIPVTMTLW YMWQVKTQR
 DEN-2 ..M..KNE.. EQTL.I..IRT G.LVI..VF. VS..I.AAA. .L.E..K..
 DEN-3 .TMR.K.D.T ENIL.V.L.T A.LI...IF. YS..A..LV. HT..KQ...
 DEN-4 N..... A.....

DEN-1 GRVIDPRRCL KPVILTCGPE RVILAGPIPV TPASAAQRRG RIGRNPAQED DQYVFSGDPL
DEN-2 E.....MD.E.M. .HS.KN.N ...IYM.E..
DEN-3 D.....MM. .V.V.QK.N ...I.M.Q..
DEN-4 P.....P.....

DEN-1 KNDEDHAWT EAKMLLDNIY TPEGIPTLF GPEREKTOAI DGEFRLRGEQ RKTFFVELMRR
DEN-2 E.....C...KNSM. E.....VD. .Y.....AD..
DEN-3 NK.....NNA. E.....SA. .Y..K.DS
DEN-4

DEN-1 GDLPVWLSYK VASAGISYKD REWCFTGERN NQILEENMEV EIWTREGEKK KL PRWLDAR
DEN-2A.R ..AE..N.A. .R...D.IK.V.K...R. ..K.....
DEN-3AH.E.K.T. .K...D.D.K.....R.....
DEN-4

DEN-1 VYSCPLALKD FKEFASGRK
DEN-2 I..D.....EA...
DEN-3 T..D.....E ..D..A...
DEN-4 ..A..M.....

COMPARISON OF THE DEDUCED NS4a AND NS4B AMINO ACID SEQUENCES OF DENGUE VIRUSES

NS4a

DEN-1 SITLDILTEI ASLPTYLSSR AKLALDNIVM LHTTERGGRA YLHALNELPE SLETLMLVAL
 DEN-2 .L..NLI..M GR...FMTQK .RD...ALV ...A.A... ..S... T...L.LT.
 DEN-3 ..A..LV... GRV.SH.AH. TRN...L.. ..S.H... .R..VE... TM...L.LG.
 DEN-4 TRN...L.. ..S.H... .R..VE... TM...L.LG.

DEN-1 LGAMTAGIFL FFMQKGIGK LSMGLITIAV ASGLLWVAEI QPQWIAASII LEFFRMVLLI
 DEN-2 .ATV.G... .L.S... MTL.MCC.IT .I...Y.Q. .H... ..LI...
 DEN-3 MILL.G.AM. .LIS... T.I...CVIA S..M..M.DV PL...SA.V ...M...
 DEN-4 T.I...CVIA S..M..M.DV PL...SA.V ...M...L....

DEN-1 PEPEKQRTQ DNQLIYVILT ILTIIGLIAA NEMGLIEKTK TDFGFYQVKT ETTILDV
 DEN-2 T...IA ..VVAATM. ..N.FL... K.L.LGSIT. QESESN...I
 DEN-3 A..VIG ..LAAIV... ..L.TTH R.L.MSKEPG VVSP.SY...
 DEN-4 T...IA ..VVAATM. ..N.FL... K.L.LGSIT. QESESN...I

DEN-1 DLRPASAWTL YAVATTILTP MLRHTIENTS ANLSLAAIAN QAAVLMGLGK GWPLHRMDLG
 DEN-2 FV... S...S. V.V..T... ..T... ..SKIHI.
 DEN-3 V... ..ST. V... ..V...D. ...ISK...
 DEN-4 FV... S...S. V.V..T... ..T... ..SKIHI.

NS4B

DEN-1 VPLLAMGCYS QVNPTTLTAS LGMLLVHYAI IGPGLOAKAT REAQKRTAAG IMKNPTVDFI
 DEN-2 I...A .LL.VA... ..A... ..G.
 DEN-3 L..I.A VLL.VT... ..G.
 DEN-4 A... .V... ..I..G.

DEN-1 TVIDLEPISY DPKFEKQLGQ VMLLVLCAGQ LLLMRTTWAF CEVLTLATGP ILTLWEGNPG
 DEN-2 P... ..I..VT. V.M...L ..A... ..S...
 DEN-3 MT...D.VI. S... ..S..L ..T...S...
 DEN-4 P... ..I..VT. V.M...L ..A... ..S...T...S...

DEN-1 RFWNNTIAVS YANIFRGSYL ACAGLAFSLI KNAQTPRR
 DEN-2 H... ..L..IM ..TTNT..
 DEN-3 K... ..M... ..L.IM .SVG.GK.
 DEN-4 T... ..L..IM ..TTNT..
 DEN-4 H... ..L..IM ..TTNT..
 DEN-4 M... ..L.IM .SVG.GK.
 DEN-4 T... ..L..IM ..TTNT..
 DEN-4 K... ..M... ..L.IM .SVG.GK.
 DEN-4 H... ..L..IM ..TTNT..
 DEN-4 RFWNNTIAVS YANIFRGSYL ACAGLAFSLI KNAQTPRR

COMPARISON OF THE DEDUCED NS5 AMINO ACID SEQUENCE OF DENGUE VIRUSES

NS5

DEN-1	GTGTTGETLG	EKWKTLQNLQ	SKSEFNTRYK	SGIMEVDRSE	AKEGLKRGET	TKHAVSRGTA
DEN-2	...NI.....	...SR..A..	GE...QI..K	...Q...TL	...I....	D.....S.
DEN-3	...SQ.....	...KK....	...RK.DL..K	...T...T.	...I....	H.....S.
DEN-4R...S.	DRK.EE...	...L...T.	...SA..D.SK	M.....SS
DEN-1	KLRWFVERNL	VKPEGKVIDL	GCGRGWSYY	CAGLKKVTEV	KGYTKGGPGH	EEPIPMATYG
DEN-2M	I...VC.G...N.R..	...L.....HS...
DEN-3M	I...R...R.....	...V..S...
DEN-4	I..I...GM	K.K.E.V..	M.TL.N....
DEN-1	WNLVKLHSGK	DVFFTPPEKC	CTLLCDIGES	SPNPTIEEGR	TLRLVKMVEP	WLRGN QFCI
DEN-2	...R.Q..V	C.....	I.....	...A...I.	...NL..N	..NN.T....
DEN-3YS..V..S.KN.
DEN-4	...Y.....	V.L.YK.T.QV	D.....	S.....SSKPE.W.
DEN-1	KILNPYMPV	VETLEQMQRK	HGGMLVRNPL	SRNSTHEMYW	VSCGTGNIVS	AVNMTSRMLL
DEN-2	...VS.....	I.KM.TL..	Y.A.....NAS.....	S..HI..H.I
DEN-3	...V.....	T.I.H..RL..I.N.....	S...V..L..
DEN-4	...V.....	T.I.E..KL..	...N..C..GAS.....	S..I..K...
DEN-1	NRFTMAHRKP	TYERDVDLGA	GRRHVAVEPE	VANLDIIGQR	IENIKNEHKS	TWHYDEDNPY
DEN-2	...K..KA	...T...S	.T.NIGI.S.	IP...T.K.	...Q..ET	S.....Q....
DEN-3	...R...R.	I.K.....	...T..NA..	TP.M.V..E.	..KR..E..S.	...DE...
DEN-4	...TR....	...K.....	...T.S.ST.TK	KPDMIISGR.	LQRLQE...E	...Q....
DEN-1	KITWAYHGSYE	VKPSGSASSM	VNGVVRLLTK	PWDVIPMVTQ	IAMTDTTPFG	QORVFKEKVD
DEN-2	T.QT.....V.....	...N.H.....
DEN-3AT.....	I...K...	...V.....	...M.....
DEN-4	R.....	PPST..P..	...K....	...C.....	...L.V..AIH..
DEN-1	TRTPRAKRGT	AQIMEVTAKW	LWGFLSRNKK	PRICTREEFT	RKVRNSAAIG	AVFVDENQWN
DEN-2	...QEP.E..	KKL.LI..E.	...KE.GKK.T	..M.....L.	..I.I..NK.K
DEN-3	...PMP..	RKV..I..E.	...RT.G..R	..L.....	...K...T...M.	...TE....D
DEN-4	...QP.P..	RMV.TT..N.	...AL.GKK.N	..L.....	...I.S.....	...R..QE.QG.T

DEN-1	SAKEAVEDER	FWDLVHRERE	LHKQKCATC	VYMMGKREK	KLGEFGKAG	SRAIWMWLG
DEN-2	..R....S.	..E..D..N	..LEC....F....
DEN-3	..RA.....	..K..D....	..L...GS.
DEN-4	..S.....S.	..E..DK..A	..QE...ES.R....
DEN-1	ARGLEFEALG	FMNEDHWFSR	ENSLSGVEGE	GLHKLGYLR	DISKIPGGNM	YADDTAGWDT
DEN-2	..F..P....	..L.....G.	..G.....V.V...E..A.I.....
DEN-3	..F.....	..L.....	..Y.....A....
DEN-4	..F.....	..L.....G.	..W.....	..R.....E E.D.KD.DL.
DEN-1	RITEDDLQNE	AKITDIMEPE	HALLATSIFK	LTYQNKVVTL	QRPANNGTVM	DVISRRDQRG
DEN-2	..L..K..	EHV.NH..G.	..KK..EA..RV ..TPR....I.....
DEN-3H..	E..QQ.D..	..RQ..NA..KV ..TPK....I...K....
DEN-4DL..	EQ.A.H	..KI..KA..FV L..TPR.A..I...KE....
DEN-1	SGQVGTGLN	TFTNMEVOLI	QMESEGVIT	QDDMQPKGL	KERVEKWSKE	CGVDRLEKRNA
DEN-2G..G..IFK	SIQHLTVTEE	IAVQN .LAR V.KE..S...
DEN-3AG..	..G...LS	KA.LE..HP.	EKKITQ.LET K.E....
DEN-4S	..A.....L..
DEN-1	ISADDCVVKP	LDERFGTSL	LL FLNDMGKVRK	DIPQWPSKG	WNDWQVPPFC	SHHFHQLIMK
DEN-2	..G.....	..D..ASA.T	A.....Q.....R.T.....I..E.V..
DEN-3I.D..ANA..	A.....Q.....	..H.....E....
DEN-4	..G.....K..E....	..A..L.KTF..
DEN-1	DGREIVVPCR	NQDELVARAR	VSQGAGWSLR	ETACLKSYA	QMWQLMYFNR	RDLRLAANAI
DEN-2	..C.VL....IG...IKT...H.
DEN-3	..KL...Q	P...IG...IT...H.S....
DEN-4	..SL.....IG...IA..	..S...H.M....
DEN-1	CSAVPVDWVP	TSRTTWSIHA	HHQWMTTEDM	LSVMNRVWIE	ENPWEMDKTP	VHSWEEVPYL
DEN-2SH...	I.....	..K.E.N....	..A...K...QE.....
DEN-3H...T.....D.....	..TT..D....
DEN-4TE.F.K.....	..D.N.T....D.I....
DEN-1	GKREDLWCGS	LIGL SSRAT	WDENIHTAIT	QVRNLIGKEE	YVDYMPVMKR	YSAPSESEGL
DEN-2Q....T....	..AK..Q..N	..S...H..	..T...S...	FRREE.EA...W
DEN-3Q....T....	..AQ..L..Q	..S...N..	..FL...R...	FRKEE...AIW
DEN-4T....	..AK.....